{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0"},{"groupId":"OG001","value":"53.3"},{"groupId":"OG002","value":"33.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"ORR: Percentage of participants who achieve best overall response Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST).\n\n* CR is defined as disappearance of all target lesions.\n* PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.","groups":[{"description":"Participants in this cohort had MTC and received 92mg/m\\^2 (maximum160 mg BID) of selpercatinib BID orally on Days 1 through 28 of a 28-day cycle.\n\nThe treatment was continued until participants experienced a progressive disease, unacceptable toxicity, or other protocol-defined reason for discontinuation.","id":"OG000","title":"Cohort 1 (Phase 2): MTC Group"},{"description":"Participants in this cohort had PTC and received 92mg/m\\^2 (maximum160 mg BID) of selpercatinib BID orally on Days 1 through 28 of a 28-day cycle.\n\nThe treatment was continued until participants experienced a progressive disease, unacceptable toxicity, or other protocol-defined reason for discontinuation.","id":"OG001","title":"Cohort 2 (Phase 2): PTC Group"},{"description":"Participants in this cohort had other (RET-altered non-thyroid) cancer and received 92mg/m\\^2 (maximum160 mg BID) of selpercatinib BID orally on Days 1 through 28 of a 28-day cycle.\n\nThe treatment was continued until participants experienced a progressive disease, unacceptable toxicity, or other protocol-defined reason for discontinuation.","id":"OG002","title":"Cohort 3 (Phase 2): Other Cancer Group"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Date of first dose to disease progression or death (Up to 62.4 Months)","title":"Phase 2: Percentage of Participants With Overall Response Rate (ORR) in Study","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}